The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice

Indian Journal of Ophthalmology

Volumn 55, Issue 6, 2007, Pages 445-450

  Hussain, Nazimul ^a   Ghanekar, Yashoda ^b   Kaur, Inderjeet ^b  

^a L V PRASAD EYE INSTITUTE   (India)

^b Hyderabad Eye Research Foundation   (India)

Author keywords

Age related macular degeneration; Angiogenesis; Anti vascular endothelial growth factor; Bevacizumab; Complement pathway; Pegaptanib; Pigment epithelium derived factor; Ranibizumab

Indexed keywords

EID: 35548939420     PISSN: 03014738     EISSN: 03014738     Source Type: Journal    
DOI: 10.4103/0301-4738.36480     Document Type: Conference Paper

References (56)

1. Csaky K. Anti-Vascular Endothelial Factor for neovascular age related macular degeneration. Ophthalmology 2003;110:879-81.
2. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et at. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-57.
3. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-13.
4. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retma 2006;26:999-1005.
5. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006;34:802-3.
6. Avery RL, Pearlman J, Pieramid DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695. e1-15.
7. Ruiter DJ, Schlingemann RO, Westphal JR, Denijn M, Rietveld FJ, De Waal RM. Angiogenesis in wound healing and rumour metastasis. Behring Inst Mitt 1993;92:258-72.
8. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336-40.
9. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001;107:409-17.
10. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Des 2003;9:1733-44.
11. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006;355:1419-31.
12. Brown DM, Kaiser PK, Michaels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus Verteporfin for neovascular age related macular degeneration. N Engl J Med 2006;355:1432-44
13. Heier JS, Boyer DS, Ciulla TA, Ferrone TJ, Jumper JM, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age related macular degeneration. Arch Ophthalmol 2006;124:1532-42.
14. Miller J, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574-84.
15. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50.
16. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
17. Malecazi F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, et al. Detection of vascular endothelial growth factorlike activity in proliferative diabetic retinopthy. Arch Ophthalmol 1994;112:1476-82.
18. Lultry GA, McLeod S, Merges C, Diggs A, Plouét J. Localization of VEGF in human retina and choroid. Arch Ophthalmol 1996;114:971-7.
19. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age related macular degeneration related choroidal neovascular membranes. Invest Ophthalmol Vis Sei 1996;37:855-68.
20. Neufeld G, Tzafra C, Gengrnovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
21. Watanabe O, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, et al. Vitreous levels of angiopoitein 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 1998;139:476-81.
22. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interIeukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-7.
23. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141:456-62.
24. Tsai DC, Charng MJ, Lee FL, Hsu WM, Chen SJ. Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization. Ophthalmoligca 2006;220:246-51.
25. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroids and eye with agerelated macular degeneration. Exp Eye Res 2006;82:99-110.
26. Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006;15:2955-61.
27. Banyasz I, Bokodi G, Vannay A, Szebeni B, Treszl A, Vasarhelyi B, et al. Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. Curr Eye Res 2006;31:685-90.
28. Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006;12:336-41.
29. Nam EJ, Han SW, Kim SU, Cho JH, Sa KH, Lee WK, et al. Association of vascular endothelial growth factor gene polymorphisms with Behcet disease in a Korean population. Hum Immunol 2005;66:1068-73.
30. Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005;333:679-85.
31. Vannay A, Dunai G, Banyasz I, Szabo M, Vamos R, Treszl A, et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res 2005;57:396-8.
32. Cooke RW, Drury JA, Mountford R, Clark D. Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sei 2004;45:1712-5.
33. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-9.
34. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, et al. Drusen complement components C3a and C5a promote choroidal neovascularizatioa Proc Natl Acad Sei 2006;103:2328-33.
35. Ebrahem Q, Renganathan K, Sears J, Vasanji A, Gu X, Lu L, et al. Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration. Proc Natl Acad Sei 2006;103:13480-4.
36. Eugene WM, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev 2006:5:123-32.
37. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for age related macular degeneration. N Engl J Med 2004;351:2805-16.
38. Jager RD, Aiello P, Patel SC, Cunningham ET Jr. Risk of intravitreous injection: A comprehensive review. Retina 2004;24:676-98.
39. Kaiser PK. Antivascular Endothelial Growth Factor Agents and their development: Therapeutic implications in ocular disease. Am J Ophthalmol 2006;142:660-8.
40. Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: A preliminary multifocal-ERG and OCT study: Ultifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 2007;114:37-44.
41. Aisenbrey S, Ziemssen F, Volker M, Gelisken F, Szurman P, Jaissle G, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:941-8.
42. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006;26:1093-4.
43. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
44. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-8.
45. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-93.
46. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevadzumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2006 Dec 1; [Epub ahead of print].
47. Jonas JB, Harder B, Spandau UH, Kamppeter BA, Libondi T, Sauder G. Bevacizumab for occult subfoveal neovascularization in agerelated macular degeneration. Eur J Ophthalmol 2006;16:774-5.
48. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr. Intravitreal Bevacizumab for choroidal neovascularisation caused by AMD (IbeNA Study): Results of a phase 1 dose escalation study. Invest Ophthalmol Vis Sei 2006;47:4569-78.
49. Costa RA, Jorge R, Calucd D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal Bevadzumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization assodated with age related macular degeneration (IbeVe Study). Graefc's Arch Clin Exp Ophthalmol 2007 Feb 28; [Epub ahead of print].
50. Takeda AL, Colquitt JL, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age related macular degeneration: A systematic review. Br J Ophthalmol 2007 May 2; [Epub ahead of print].
51. Brown MM, Brown GC, Brown H. Value based medicine and interventions for macular degeneration. Curr Opin Ophthalmol 2007;18:194-200.
52. Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:75-6.
53. Schaal KB, Hoh AE, Scheuerle A, Schutt F, Dithmar S. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 2007;104:285-9.
54. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007 Mar 14; [Epub ahead of print]
55. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006;37:144-6.
56. Kroll P, Meyer CH. Which treatment is best for which AMD patient? Br J Ophthalmol 2006;90:128-30.